<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02158624</url>
  </required_header>
  <id_info>
    <org_study_id>13-E-09</org_study_id>
    <nct_id>NCT02158624</nct_id>
  </id_info>
  <brief_title>Ranibizumab Treatment for Age-Related Macular Degeneretion</brief_title>
  <acronym>QUATRO</acronym>
  <official_title>The Correlation for Improvement of Visual Acuity and QOL After Ranibizmab Treatment for Age-Related Macular Degeneration Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyushu University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Occupational and Environmental Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kurume University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fukuoka University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Research Support Center Kyush</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Kyushu University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish the correlation between visual acuity improvement and QOL measurement after
      ranibizumab treatment for AMD patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline change of visual acuity and QOL after ranibizumab treatment</measure>
    <time_frame>3 months</time_frame>
    <description>Analyze the correlation between visual acuity improvement and QOL assessment using VFQ-25 and Patient Satisfaction Questionnaire before and after initial ranibizumab treatment for AMD patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the correlation between the changes of visual acuity and QOL measurement during one year follow-up observations</measure>
    <time_frame>1year</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Baseline change of central retinal thickness by OCT examination.</measure>
    <time_frame>3 months, 1 year</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Visual Disorder Due to Age-related Macula Degeneration</condition>
  <arm_group>
    <arm_group_label>Ranibizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Lucentis 0.5mg</intervention_name>
    <arm_group_label>Ranibizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Active primary or recurrent subfoveal choroidal neovascularization lesion due to AMD

          -  Subjects of either gender age 50 years or older

          -  Visual acuity better than 0.05 decimal( 20/400 Snellen)

          -  Signed informed consent form

        Exclusion Criteria:

          -  Prior treatment for neovascular AMD in the study eye, for example, PDT or anti-VEGF
             therapy

          -  Patients whose lesion site evaluated by FA examination is more than 12DA in subject
             eye

          -  Patients with treatment of triamcinolone intravitreal injection within 6 months in
             subject eye

          -  Patients with a history of intraocular surgical operation(including cataract)within 3
             months in subject eye

          -  Patients with serious allergic history to such as fluorescein, indocyanine green,
             iodophors

          -  The pregnant or lactating woman
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tatsuro Ishibashi, MD. PhD</last_name>
    <phone>+81-92-642-5648</phone>
    <email>ishi@eye.med.kyushu-u.ac.jp</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yuji Oshima, MD. PhD</last_name>
    <phone>+81-92-642-5648</phone>
    <email>yuji@eye.med.kyushu-u.ac.jp</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Ophthalmology, Kyushu University Hospital</name>
      <address>
        <city>Maidashi, Higashiku, Fukuoka-city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuji Oshima, MD. PhD</last_name>
      <phone>+81-92-642-5648</phone>
      <email>yuji@eye.med.kyushu-u.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 5, 2014</study_first_submitted>
  <study_first_submitted_qc>June 5, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 9, 2014</study_first_posted>
  <last_update_submitted>June 5, 2014</last_update_submitted>
  <last_update_submitted_qc>June 5, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyushu University</investigator_affiliation>
    <investigator_full_name>Yuji Oshima</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ranibizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

